Introduction
inflammatory response [6] [7] [8] and reduction of thrombus generation [9] . Further evidence has suggested the pleiotropic effects of statins could extend to prevention and treatment of different cancers [10, 11] .
Regarding prevention, several studies have reported a correlation between statins use, for cardiovascular motives, and the reduction of cancer incidence [12, 13] . A retrospective nested case-control study, in close to half a million patients, demonstrated a 48% reduction in renal cell carcinoma, irrespective of age, sex, obesity or tobacco use [14] . However, a recent systematic review of 42 randomized trials failed to demonstrate cancer risk reduction after statin use [15] . In fact, contradictory results were observed, with increased incidence for certain cancers (i.e. melanoma) and reduced incidence for others (i.e. stomach, liver and lymphoma) [15] . The reasons of the discrepancy may include different designs (retrospective versus prospective), insufficient follow-up and more importantly, different type of statins used [16] . [17] . The more lipophilic statins achieve higher levels of exposure in non-hepatic tissues, while the hydrophilic statins are more hepatoselective [18, 19] [20] [21] [22] .
Statins belong from two classes: hydrophilic (pravastatin and rosuvastatin) and lipophilic (cerivastatin, simvastatin, lovastatin, fluvastatin and atorvastatin). Lipophilicity of statins improves drug access to different tissues

. Thus, a differential effect of statins can be predicted among hepatic and nonhepatic tissues. Evidence from randomized controlled clinical trials and in vitro studies support this differential effect of statins depending on its class (lipophilic versus hydrophilic) and the specific tissue assayed
Little is known about the effect of statins on gynaecological cancer incidence. A Canadian study, analysing the effect of statins on the incidence of cancer, showed reduction in the majority of cancers, including uterine cancer [20] . In contrast, a recent retrospective cohort study [23] did not show a correlation between statin use and reduced incidence of endometrial or ovarian cancer.
Less information exists regarding the use of statins to treat gynaecological cancers. A retrospective study suggests that statins improved overall survival in patients with epithelial ovarian cancer if they were current statin users when receiving standard therapy [24] . Preliminary in vitro studies suggest that lovastatin, and possibly atorvastatin, could induce cell death in ovarian cancer cell lines [25, 26] 
Primary cultures
Primary cultures of human tissues were established following protocols previously published by our group [27] 
Flow cytometry analysis
Cell cycle distribution and the detection of a sub-G1 apoptotic peak were analysed by flow cytometry using propidium iodide DNA staining following protocol previously described [28] . 
Measurement of caspase activity
RT-PCR
Total RNA was isolated using the Chomczynski method [29] . cDNA was generated using reverse transcriptase (Superscript II, Invitrogen (Fig. 4B ). (Fig. 7) . (Fig. 8A) . Figure 8B shows [35] . In vitro studies in ovarian cancer cells have shown that farnesyl and geranylgeranyl pyrophosphate could revert the effect in cell viability induced by lovastatin [25, 26] . Therefore, we decided to investigate if any of these isoprenes could affect cell death induced by simvastatin in cell lines and primary tissue cultures from gynaecological cancers. As shown in Figure 9 , the addition of geranylgeranyl but not farnesyl pyrophosphate almost completely abrogates the effect in cell viability induced by both statins in the A2780 cells and Hela cells. Similar effect was observed with two primary cultures established from ovarian cancer (indicated as ovarian ca 6 in the Fig. 9 ) and uterine cancer (data not shown). Figure 10A , chemotherapy drastically reduces the cell viability of cells of both normal and cancerous ovarian origin. In contrast, lovastatin and (Fig. 10B) and cancerous primary tissue cultures (data not shown). However, a synergistic effect is observed if same concentrations of statins are combined with lower concentrations of chemotherapies (Fig. 10C) 
Statins induce caspase-mediated apoptosis through activation of intrinsic and extrinsic cascades
To characterize the mechanisms involved in statin-mediated apoptosis, we further analysed statin effect on the A2780 ovarian cancer cell line. First at all, we investigated if the cell death could involve the activation of caspase cascade. Figure 5A shows an increase in both caspase-8 (the major caspase initiator of the extrinsic pathway) and caspase-9 (a caspase initiator of intrinsic pathway) activity after 24 hrs of incubation with lovastatin or simvastatin (1 and 10 M). The non-selective caspase inhibitor ZVADfmk reverted the loss of cell viability induced by statins, proving lovastatin-and simvastatin-mediated apoptosis occurs through caspase-dependent mechanisms (Fig. 5B). To further investigate
Fig. 4 (A) Detection by immunoblotting of the cleaved form of PARP after treatment with increasing concentrations of lipophilic (lovastatin and simvastatin) or hydrophilic (pravastatin) statins in Ishikawa (indicated as IK) and Hela cells. Actin is used as loading control. Cϩ stands for positive control. (B) Absence of effects in cell viability of different concentrations (1-10 uM) of lovastatin (Lov) and simvastatin (Sim) in tissue cultures established from normal gynaecological origin tissues. Cell viability was measured by MTS assays upon 48 hrs of treatment. the use of both the intrinsic and extrinsic apoptotic pathways, the expression of key proteins from each pathway were analysed. We found that increasing concentrations of statins decrease levels of FLIP protein (an inhibitor of the DISC complex) and pro-caspase 8 but increase the cleaved form (active caspase 8), thus indicating the activation of extrinsic pathway. On the other hand, a decrease in cytosolic BAD, release of cytochrome c from mitochondria and the cleavage of caspase-9 also occur upon treatment with lovastatin and simvastatin, indicating activation of the intrinsic pathway (Fig. 6). The decrease in BID protein suggests a communication between both pathways, given that BID is cleaved after activation of extrinsic pathway and facilitates the release of proteins involved in the intrinsic pathway.
Differential expression of HMG-CoA reductase between statin-sensitive and -resistant cells
It has been suggested in previous publications that some cancer cells depend on the high levels of mevalonate and other intermediate metabolites in the biosynthesis of cholesterol to mediate their cell proliferation and evasion of apoptotic signals [33]. Thus, the depletion of these metabolites would lead to preferential cell death in cancerous cells as opposed to normal cells. We analysed the levels of HMG-CoA reductase (the key enzyme, inhibited by statins, directly responsible for mevalonate levels) in all the cell lines and primary tissue cultures established from female human
Fig. 5 (A) Measurement of caspase-8 and -9 activities through an in vitro caspase assay in A2780 cells after 48 hrs of treatment with increasing concentrations of lovastatin (Lov) and simvastatin (Sim). Activity is expressed as per cent from control. (B) Effects in cell viability of both statins in the presence or absence of a non-selective caspase inhibitor (ZVADfmk). Data are shown as mean -/ϩ SD (n ϭ 3). The * indicates statistical significance compared to control (vehicle), (Mann-Whitney test, P-value Ͻ 0.05). reproductive tissues. Interestingly, all the cells sensitive to statinmediated apoptosis expressed higher levels of HMG-CoA reductase compared with those non-sensitive to statin effect (including all the normal cells and the primary tissue culture from the undifferentiated endometrial sarcoma)
Mevalonate and geranylgeranyl pyrophosphate but not farnesyl pyrophosphate rescue cancer cells from statin-mediated apoptosis
To confirm that cell death induced by lipophilic statins in gynaecological cancers is due to the decrease in the synthesis of mevalonate (through inhibition of HMGCoA reductase by statins), we analysed if statin-mediated cell death could be rescued by the supplementation of mevalonate in A2780 and Hela cells. In accordance with our theory, we demonstrated that mevalonate supplementation prevented the loss of cell viability induced by statins in A2780 cells
Synergistic effect on cell viability by the combination of statins and chemotherapies in primary tissue cultures of ovarian and uterine cancers
Discussion
In recent years, the potential benefit of statins to reduce the incidence of a wide range of cancers has been discussed [11, 13, 15, 16, 23] . In addition to its chemopreventive effects, a potential role as therapeutic tool has been postulated for statins, based principally on in vitro studies [21, 26, 36] [24] [25] [26] [43, 44] while inducing apoptosis in human hepatocytes [45] and osteocarcinoma cells [37] [26] .
We demonstrated that tissues sensitive to statins correlates to levels of HMG-CoA evaluated by mRNA (Fig. 7) . [4] . We demonstrated that co-incubation with GPP but not FPP completely reverses the loss in viability in ovarian, endometrial and cervical cancer cells, suggesting that geranylgeranylated proteins (GPP proteins) are also important to the survival of these cancer cells (Fig. 9) . In addition, the disruption of localization and function of GPP proteins affects crosstalk and activation of other signal transduction pathways involved in growth and survival of cancer cells and exposes the cells to a pro-apoptotic environment [21, 47, 48] . In this sense, changes in cholesterol concentrations within membrane domains lead to recruitment, detachment or retention at these sites of protein kinases required in cell growth, proliferation and invasiveness [48, 49] . For example, in osteoblasts, the mechanism by which lovastatin promotes differentiation involves rapid activation of Ras, which associates with and activates PI3K in the plasma membrane, which in turn regulates Akt and MAPK activities [47] . Recently, Liu et [51] . As shown in Figure 10, 
